GLP-1 receptor agonists have demonstrated potential in raising high-density lipoprotein (HDL) cholesterol and decreasing levels of low-density lipoprotein (LDL) cholesterol and triglycerides, as well as improving lipid profiles in T1D patients. Here, GLP1R is linked to type 1 diabetes mellitus.